Neurocrine Biosciences Announces Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (Valbenazine) For The Treatment Of Tardive Dyskinesia Post author:Sam Post published:March 20, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like 3 Drug Giants That Boasts the Best Pipelines April 9, 2017 Bay Area's Biggest Startup Factory Looks to Fund This New Type of Biotech July 4, 2017 Biogen Taps Biotech Vet as New CFO November 20, 2017